References
|
1. Australian Resuscitation C, New Zealand Resuscitation C. Management of specific dysrhythmias in paediatric advanced life support. ARC and NZRC Guideline 2010. Emergency medicine Australasia: EMA. 2011;23:409-11.
2. Wanless RS, Anderson K, Joy M, Joseph SP. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. American heart journal. 1997;133:441-6.
3. Celiker A, Ayabakan C, Ozer S, Ozme S. Sotalol in treatment of pediatric cardiac arrhythmias. Pediatrics international : official journal of the Japan Pediatric Society. 2001;43:624-30.
4. Knudson JD, Cannon BC, Kim JJ, Moffett BS. High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatric cardiology. 2011;32:896-903.
5. Laer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Zhang W, Hulpke-Wette M. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. Journal of the American College of Cardiology. 2005;46:1322-30.
6. Price JF, Kertesz NJ, Snyder CS, Friedman RA, Fenrich AL. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age. Journal of the American College of Cardiology. 2002;39:517-20.
7. Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. Journal of pharmacokinetics and pharmacodynamics. 2001;28:555-75.
8. Saul JP, Schaffer MS, Karpawich PP, Erickson CC, Epstein MR, Melikian AP, Shi J, Karara AH, Cai B, Hinderling PH. Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia. Journal of clinical pharmacology. 2001;41:35-43.
9. Khalil F, Laer S. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. The AAPS journal. 2014;16:226-39.
10. Hickey CN, Mycyk MB, Wahl MS. Can a poison center overdose guideline safely reduce pediatric emergency department visits for unintentional beta-blocker ingestions? American journal of therapeutics. 2012;19:346-50.
11. Wax PM, Erdman AR, Chyka PA, Keyes DC, Caravati EM, Booze L, Christianson G, Woolf A, Olson KR, Manoguerra AS, Scharman EJ, Troutman WG. beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clinical toxicology. 2005;43:131-46.
12. Australian Injectable Drugs Handbook, 6th Edition, Society of Hospital Pharmacists of Australia 2014
|
